Steffan N. Ho

16.6k total citations · 4 hit papers
51 papers, 14.6k citations indexed

About

Steffan N. Ho is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Steffan N. Ho has authored 51 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 14 papers in Oncology and 14 papers in Immunology. Recurrent topics in Steffan N. Ho's work include Signaling Pathways in Disease (15 papers), Aldose Reductase and Taurine (8 papers) and RNA Interference and Gene Delivery (6 papers). Steffan N. Ho is often cited by papers focused on Signaling Pathways in Disease (15 papers), Aldose Reductase and Taurine (8 papers) and RNA Interference and Gene Delivery (6 papers). Steffan N. Ho collaborates with scholars based in United States, United Kingdom and Italy. Steffan N. Ho's co-authors include Larry R. Pease, Robert M. Horton, Jeffrey K. Pullen, Henry D. Hunt, Gerald R. Crabtree, Neil A. Clipstone, Jeffrey P. Northrop, Luika Timmerman, Stuart L. Schreiber and William Y. Go and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Steffan N. Ho

51 papers receiving 14.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Site-directed mutagenesis by overlap extension using the polymerase chain reaction

1989 6.9k citations Steffan N. Ho et al. profile →
Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension

1989 2.8k citations Steffan N. Ho et al. profile →
The Mechanism of Action of Cyclosporin A and FK506

1996 562 citations Steffan N. Ho, Neil A. Clipstone et al. profile →
NF-AT components define a family of transcription factors targeted in T-cell activation

1994 512 citations Jeffrey P. Northrop, Steffan N. Ho et al. Nature profile →

Peers

Countries citing papers authored by Steffan N. Ho

Since Specialization

Citations

This map shows the geographic impact of Steffan N. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steffan N. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steffan N. Ho more than expected).

Fields of papers citing papers by Steffan N. Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steffan N. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steffan N. Ho. The network helps show where Steffan N. Ho may publish in the future.

Co-authorship network of co-authors of Steffan N. Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Steffan N. Ho. A scholar is included among the top collaborators of Steffan N. Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steffan N. Ho. Steffan N. Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer 2018 ·Annals of Oncology ·Jean‐Charles Soria, Steffan N. Ho, Marileila Varella‐Garcia, A. John Iafrate, Benjamin Solomon, Alice T. Shaw, Fiona Blackhall, Tony Mok, Yi‐Long Wu, Ekaterina Pestova, Keith D. Wilner, Anna Polli, Jolanda Paolini, Silvana Lanzalone, (unknown), D. Ross Camidge	12
2	A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib 2017 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), Shalini Singh, J. Burns Amberson, (unknown), Zoran Gatalica, Steffan N. Ho, Isabell R. Loftin, Abigail McElhinny, Penny Towne	38
3	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer 2016 ·Journal of Thoracic Oncology ·Sai‐Hong Ignatius Ou, Ramaswamy Govindan, Keith D. Eaton, Gregory A. Otterson, Martin Gutierrez, Alain C. Mita, Athanassios Argiris, Nicoletta Brega, Tiziana Usari, Weiwei Tan, Steffan N. Ho, Francisco Robert	40
4	Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine 2013 ·International Journal of Oncology ·Kandasamy Hariharan, Peter Chu, (unknown), (unknown), (unknown), Arturo Molina, Steffan N. Ho, Mario I. Vega, Benjamin Bonavida	8
5	Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment 2013 ·Genomics ·Donghui Huang, Dong‐Wan Kim, Αthanasios Kotsakis, Shibing Deng, Paul D. Lira, Steffan N. Ho, Nathan V. Lee, (unknown), Joan Cao, James G. Christensen, Tae Min Kim, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Mao Mao	34
6	New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In Situ Hybridization Assay 2013 ·Journal of Thoracic Oncology ·Hiroaki Nitta, Koji Tsuta, Akihiko Yoshida, Steffan N. Ho, Brian Kelly, (unknown), (unknown), Katie White, (unknown), Penny Towne, (unknown), Abigail McElhinny, Jim Ranger‐Moore, (unknown), Shalini Singh, Hitoshi Tsuda, Thomas M. Grogan	24
7	100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc) 2012 ·Annals of Oncology ·Richard S. Finn, John Crown, Katalin Boér, István Láng, (unknown), Aurora Breazna, Steffan N. Ho, (unknown), Sophia Randolph, DJ Slamon	30
8	Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response 2010 ·Molecular Cancer Therapeutics ·Jianying Dong, Stephen J. Demarest, Arlene Sereno, (unknown), Emma Langley, (unknown), (unknown), (unknown), Ingrid B.J. Joseph, Scott Glaser, Steffan N. Ho, Mitchell E. Reff, Kandasamy Hariharan	48
9	Intracellular water homeostasis and the mammalian cellular osmotic stress response 2005 ·Journal of Cellular Physiology ·Steffan N. Ho	96
10	The role of NFAT5/TonEBP in establishing an optimal intracellular environment 2003 ·Archives of Biochemistry and Biophysics ·Steffan N. Ho	59
11	The Osmoprotective Function of the NFAT5 Transcription Factor in T Cell Development and Activation 2002 ·The Journal of Immunology ·Jason P. Trama, William Y. Go, Steffan N. Ho	83
12	Optimization and direct comparison of the dimerizer and reverse tet transcriptional control systems 2002 ·The Journal of Gene Medicine ·William Y. Go, Steffan N. Ho	19
13	The NFAT-Related Protein NFATL1 (TonEBP/NFAT5) Is Induced Upon T Cell Activation in a Calcineurin-Dependent Manner 2000 ·The Journal of Immunology ·Jason P. Trama, Qingjun Lu, Robert G. Hawley, Steffan N. Ho	135
14	Transcriptional control in keratinocytes and fibroblasts using synthetic ligands. 1997 ·Journal of Clinical Investigation ·Rachel A. Freiberg, Steffan N. Ho, Paul A. Khavari	13
15	Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization 1996 ·Current Biology ·David M. Spencer, Peter J. Belshaw, Lei Chen, Steffan N. Ho, Filippo Randazzo, Gerald R. Crabtree, Stuart L. Schreiber	133
16	Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression 1996 ·Nature ·Luika Timmerman, Neil A. Clipstone, Steffan N. Ho, Jeffrey P. Northrop, Gerald R. Crabtree	458
17	Cloning and chromosomal localization of the human and murine genes for the T-cell transcription factors NFATc and NFATp 1995 ·Cytogenetic and Genome Research ·(unknown), Steffan N. Ho, Joseph M. Luna, Joseph C. Giacalone, Daniel Thomas, Luika Timmerman, Gerald R. Crabtree, Uta Francke	24
18	NFATc3, a Lymphoid-specific NFATc Family Member That Is Calcium-regulated and Exhibits Distinct DNA Binding Specificity 1995 ·Journal of Biological Chemistry ·Steffan N. Ho, Daryl J. Thomas, Luika Timmerman, Xu Li, Uta Francke, Gerald R. Crabtree	156
19	Cloning and Characterization of NF-ATc and NF-ATp: The Cytoplasmic Components of NF-AT 1994 ·Advances in experimental medicine and biology ·Steffan N. Ho, Luika Timmerman, Jeffrey P. Northrop, (unknown)	8
20	Increased specificity of PCR-amplified products by size-fractionation of restriction enzyme-digested template genomic DNA 1988 ·Nucleic Acids Research ·Barbara Beck, Steffan N. Ho	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact